List of Viekira Xr drug patents
Viekira Xr is owned by Abbvie Inc.
Viekira Xr contains Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir.
Viekira Xr has a total of 20 drug patents out of which 0 drug patents have expired.
Viekira Xr was authorised for market use on 22 July, 2016.
Viekira Xr is available in tablet, extended release;oral dosage forms.
Viekira Xr can be used as treatment of hcv infection using paritaprevir, treatment of hcv infection using ombitasvir, treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin, treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin., treatment of hcv infection using dasabuvir, use of dasabuvir to inhibit viral replication for the treatment of hcv infection., treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination.
The generics of Viekira Xr are possible to be released after 02 January, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Sep, 2028
(5 years from now) | |
| US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(6 years from now) | |
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 4 months from now) | |
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 4 months from now) | |
| US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(5 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
| US10201541 | ABBVIE INC | Compositions and methods for treating HCV |
May, 2032
(9 years from now) | |
| US10201584 | ABBVIE INC | Compositions and methods for treating HCV |
May, 2032
(9 years from now) | |
| US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US10105365 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) | |
| US9744170 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) | |
| US9333204 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) | |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR family patents
110
United States
30
European Union
27
Japan
26
Spain
24
China
19
Portugal
18
Denmark
18
Canada
16
Hong Kong
16
Poland
16
Taiwan, Province of China
15
Slovenia
15
Croatia
13
South Africa
13
Mexico
13
Germany
13
Cyprus
13
Chile
12
Uruguay
12
Argentina
12
Korea, Republic of
12
New Zealand
11
Hungary
11
EA
10
Brazil
10
Peru
10
United Kingdom
9
Israel
9
Dominican Republic
8
Lithuania
8
Guatemala
8
Ecuador
8
Ukraine
8
RS
7
Australia
7
Singapore
6
Norway
5
Costa Rica
4
Turkey
4
Colombia
4
Sweden
4
Malaysia
4
Netherlands
4
Luxembourg
3
Austria
3
Philippines
2
Russia
2
Switzerland
2
ME
1
El Salvador
1
San Marino
1
Georgia
1
Panama
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic